J. Oldenburg

发表

Inter-locus as well as intra-locus heterogeneity in LINE-1 promoter methylation in common human cancers suggests selective demethylation pressure at specific CpGs

R. Fimmers, H. Fröhlich, W. Schulz, 2015, Clinical Epigenetics.

A new cell culture‐based assay quantifies vitamin K 2,3‐epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol‐driven VKOR assay

C. Müller, J. Oldenburg, A. Fregin, 2013, Journal of thrombosis and haemostasis : JTH.

Molecular Biology of Blood Coagulation

J. Oldenburg, R. Schwaab, 2001, Seminars in thrombosis and hemostasis.

Effect of F8 B domain gene variants on synthesis, secretion, activity and stability of factor VIII protein

J. Oldenburg, A. Pavlova, J. Driesen, 2013, Thrombosis and Haemostasis.

The Plasma Factor XIII Heterotetrameric Complex Structure: Unexpected Unequal Pairing within a Symmetric Complex

J. Pellequer, A. Biswas, J. Oldenburg, 2019, Biomolecules.

The Plasma Factor XIII Heterotetrameric Complex Structure: Unexpected Unequal Pairing within a Symmetric Complex

J. Pellequer, A. Biswas, J. Oldenburg, 2019, bioRxiv.

Revisiting the mechanism of coagulation factor XIII activation and regulation from a structure/functional perspective

Christoph A. Krettler, A. Biswas, J. Oldenburg, 2016, Scientific Reports.

Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel

C. Königs, J. Oldenburg, G. Auerswald, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study

J. Oldenburg, M. Morfini, G. Castaman, 2020, British journal of haematology.

octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment

J. Oldenburg, A. Klukowska, V. Komrska, 2020, Therapeutic advances in hematology.

Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi‐centre, non‐interventional study

J. Oldenburg, E. Santagostino, M. Recht, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors

J. Oldenburg, R. Ljung, E. Santagostino, 2017, Thrombosis and Haemostasis.

Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety

J. Oldenburg, T. Lissitchkov, C. Hay, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Spotlight on the human factor: building a foundation for the future of haemophilia A management

J. Oldenburg, K. Khair, C. Kessler, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity

S. Lacroix-Desmazes, J. Oldenburg, D. Lillicrap, 2015, Haematologica.

nonsevere hemophilia A ) mutation and risk of inhibitor development in F8 Factor VIII gene (

J. Astermark, R. Keenan, J. Oldenburg, 2014 .

Patient data meta‐analysis of Post‐Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF‐PFM

A. Iorio, M. Marcucci, J. Oldenburg, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Expression studies of mutant factor VIII alleles with premature termination codons with regard to inhibitor formation

C. Müller, J. Oldenburg, S. Rost, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

GENERAL INTRODUCTION AND OUTLINE OF THE THESIS

J. Astermark, R. Keenan, J. Oldenburg, 2012 .

THROMBOSIS AND HEMOSTASIS Factor VIII gene ( F 8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

J. Astermark, R. Keenan, J. Oldenburg, 2013 .

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.

M. Margaglione, S. Cessie, S. le Cessie, 2012, Blood.

Understanding FVIII/VWF complex – report from a symposium of XXIX WFH meeting 2010

J. Oldenburg, A. Federici, N. Ewing, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐α and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia A

R. Fimmers, J. Astermark, S. Lacroix-Desmazes, 2009, Journal of thrombosis and haemostasis : JTH.

Efficacy, safety and tolerability of recombinant factor VIII (REFACTO®) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria

A. Ganser, J. Oldenburg, R. Klamroth, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors in PTP'S: A Retrospective Study in Germany

J. Oldenburg, W. Miesbach, C. Auer, 2006 .

Genetic defects and inhibitor development in siblings with severe hemophilia

J. Astermark, J. Oldenburg, G. White, 2005 .

The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A.

J. Astermark, J. Oldenburg, E. Berntorp, 2005, Haematologica.

Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation

J. Oldenburg, R. Schwaab, E. Tuddenham, 1995, Thrombosis and Haemostasis.

Novel characterization of a breakpoint in F8: an individualized approach to gene analysis when PCR and MLPA results contradict

J. Oldenburg, O. el-Maarri, M. D. Williams, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Detection and characterisation of two missense mutations at a cleavage site in the factor VIII light chain.

J. Oldenburg, R. Schwaab, H. Brackmann, 1991, Thrombosis research.

Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies.

J. Oldenburg, R. Schwaab, H. Brackmann, 1996, American journal of human genetics.

Somatic mosaicism in hemophilia A: a fairly common event.

J. Oldenburg, R. Ljung, A. Fregin, 2001, American journal of human genetics.

Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data

C. Müller, J. Oldenburg, S. Rost, 2001, British journal of haematology.

11 Hemophilia A Patients without Mutations in the Factor VIII Encoding Gene

N. Klopp, J. Oldenburg, J. Graw, 2002, Thrombosis and Haemostasis.

Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males

Rainer Schwaab, Tim Becker, T. Wienker, 2007, Human Genetics.

Quality management and quality assurance in haemophilia care: a model at the Bonn haemophilia centre

P Hanfland, J. Oldenburg, R. Schwaab, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

von Willebrand factor propeptide missense variants affect anterograde transport to Golgi resulting in ER retention

A. Biswas, J. Oldenburg, A. Naz, 2021, Human mutation.

Insights into pathological mechanisms of missense mutations in C-terminal domains of von Willebrand factor causing qualitative or quantitative von Willebrand disease

A. Biswas, J. Oldenburg, A. Pavlova, 2013, Haematologica.

Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease.

J. Oldenburg, R. Schwaab, Z. Ruggeri, 2001, Blood.

Patients with familial biparental hydatidiform moles have normal methylation at imprinted genes

M. Seoud, J. Walter, G. Rouleau, 2005, European Journal of Human Genetics.

A common 253‐kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3

R. Marschalek, J. Oldenburg, G. Castaman, 2007, Journal of thrombosis and haemostasis : JTH.

Results of a Screening for von Willebrand Disease Type 2N in Patients with Suspected Haemophilia A or von Willebrand Disease Type 1

J. Oldenburg, R. Schwaab, R. Schneppenheim, 1996, Thrombosis and Haemostasis.

Functional and Structural Characterization of Nucleic Acid Ligands That Bind to Activated Coagulation Factor XIII

A. Biswas, J. Oldenburg, G. Mayer, 2021, Journal of clinical medicine.

Selective Modulation of the Protease Activated Protein C Using Exosite Inhibiting Aptamers.

J. Oldenburg, G. Mayer, Fabian Tolle, 2020, Nucleic acid therapeutics.

Capture and Release (CaR): a simplified procedure for one-tube isolation and concentration of single-stranded DNA during SELEX.

J. Oldenburg, G. Mayer, Fabian Tolle, 2015, Chemical communications.

Elucidation of Gross Genomic Rearrangements Involving Large Deletions in the Clotting Factor VIII Gene

J. Oldenburg, H. Schneider, C. Mühle, 2008 .

Evaluation of DHPLC in the analysis of hemophilia A.

C. Müller, B. Weber, J. Oldenburg, 2001, Journal of biochemical and biophysical methods.

Environmental and genetic factors influencing inhibitor development.

J. Oldenburg, R. Schwaab, E. Tuddenham, 2004, Seminars in hematology.

Heterozygous large deletions of Factor 8 gene in females identified by multiplex PCR‐LC

J. Oldenburg, O. el-Maarri, D. Delev, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor.

T. Madhusudhan, B. Isermann, J. Oldenburg, 2009, Chemistry & biology.

Fifteen years of Env C2V3C3 evolution in six individuals infected clonally with human immunodeficiency virus type 1

Thomas Lengauer, R. Kaiser, M. Däumer, 2007, Journal of medical virology.

Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family

J. Oldenburg, R. Schwaab, P. Hanfland, 2000, British journal of haematology.

Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).

J. Oldenburg, A. Chuansumrit, E. Santagostino, 2016, Thrombosis research.

Protection From Type 1 Diabetes by Vitamin D Receptor Haplotypes

K. Badenhoop, J. Oldenburg, V. Ivaškevičius, 2006, Annals of the New York Academy of Sciences.

Phylogeny of the Vitamin K 2,3-Epoxide Reductase (VKOR) Family and Evolutionary Relationship to the Disulfide Bond Formation Protein B (DsbB) Family

Christoph A. Krettler, J. Oldenburg, M. Watzka, 2015, Nutrients.

Gain‐of‐Function Mutation in STIM1 (P.R304W) Is Associated with Stormorken Syndrome

K. Zerres, J. Oldenburg, P. Nürnberg, 2014 .

Profiling of active thrombin in human blood by supramolecular complexes.

J. Oldenburg, G. Mayer, Jens Müller, 2011, Angewandte Chemie.

Tamoxifen induces resistance to activated protein C.

R. Fimmers, J. Oldenburg, W. Kuhn, 2014, Thrombosis research.

Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era

J. Oldenburg, Jens Müller, B. Pötzsch, 2018, Thrombosis and Haemostasis.

The importance of inhibitor eradication in clinically complicated hemophilia A patients

J. Oldenburg, E. Santagostino, G. Young, 2018, Expert review of hematology.

F8 Inversions at Xq28 Causing Hemophilia A Are Associated With Specific Methylation Changes: Implication for Molecular Epigenetic Diagnosis

M. Jamil, Amit Sharma, J. Oldenburg, 2019, Front. Genet..

In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies

A. Biswas, H. Singer, J. Oldenburg, 2019, Annals of Hematology.

Activity Pattern Analysis Indicates Increased but Balanced Systemic Coagulation Activity in Response to Surgical Trauma

J. Oldenburg, D. Wirtz, G. Mayer, 2018, TH Open.

Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays

J. Oldenburg, D. Delev, A. Pavlova, 2014, Thrombosis and Haemostasis.

Monitoring of plasma levels of activated protein C using a clinically applicable oligonucleotide‐based enzyme capture assay

J. Oldenburg, S. Gravius, Max Friedrich, 2012, Journal of thrombosis and haemostasis : JTH.

Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment

C. Müller, E. Seifried, J. Oldenburg, 2011, Journal of thrombosis and haemostasis : JTH.

GGCX mutations show different responses to vitamin K thereby determining the severity of the hemorrhagic phenotype in VKCFD1 patients

V. Hornung, A. Biswas, H. Singer, 2021, Journal of thrombosis and haemostasis : JTH.

Elastin Polymorphism Haplotype and Intracranial Aneurysms Are Not Associated in Central Europe

W. Poewe, H. Steinmetz, W. Deinsberger, 2003, Stroke.

Male-to-female transmission of HIV in a cohort of hemophiliacs — Frequency, risk factors and effect of sexual counseling

G. Lüchters, R. Kaiser, T. Sauerbruch, 2005, Infection.

Regulation of human factor IX expression using doxycycline-inducible gene expression system

Xiaomin Wang, H. Fechner, J. Oldenburg, 2003, Thrombosis and Haemostasis.

Osteoporosis in haemophilia – an underestimated comorbidity?

T. Wallny, J. Oldenburg, B. Stoffel‐Wagner, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Monitoring the progression of the in vitro selection of nucleic acid aptamers by denaturing high-performance liquid chromatography

Günter Mayer, J. Oldenburg, O. el-Maarri, 2008, Analytical and bioanalytical chemistry.

Relative Hyperhomocysteinemia in Patients with Panic Disorder: A Case-Control Study

J. Oldenburg, K. Imbierowicz, D. Klingmüller, 2010, Neuropsychobiology.

The Current Understanding of Molecular Pathogenesis of Quantitative von Willebrand Disease, Types 1 and 3

J. Oldenburg, H. Yadegari, 2020, Hämostaseologie.

Impact of Hormone-Associated Resistance to Activated Protein C on the Thrombotic Potential of Oral Contraceptives: A Prospective Observational Study

J. Oldenburg, W. Kuhn, J. Welz, 2014, PloS one.

Variability in Clinical Phenotype of Hemophilia : Role of the F 8 / F 9 Genotype

J. Oldenburg, A. Pavlova, 2013 .

Thrombin inhibition profiles in healthy individuals and thrombophilic patients

R. Fimmers, J. Oldenburg, G. Mayer, 2012, Thrombosis and Haemostasis.

Dynamic of Thrombin Generation in Patients with Severe Hemophilia A

J. Oldenburg, H. Brackmann, F. Wenzel, 2008 .

Molecular Analysis of Fetal and Adult Primary Human Liver Sinusoidal Endothelial Cells: A Comparison to Other Endothelial Cells

N. Nüsgen, M. Jamil, H. Singer, 2020, International journal of molecular sciences.

VKORC1 and VKORC1L1: Why do Vertebrates Have Two Vitamin K 2,3-Epoxide Reductases?

J. Oldenburg, M. Watzka, C. Bevans, 2015, Nutrients.

Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A

J. Oldenburg, M. Spannagl, Jens Müller, 2019, Thrombosis and Haemostasis.

Impact of Telemedicine Tools on Record Keeping and Compliance in Haemophilia Care.

J. Oldenburg, C. Klein, T. Frankenberger, 2019, Hamostaseologie.

Skewed X-chromosome inactivation and XIST locus methylation levels do not contribute to the lower prevalence of Parkinson's disease in females

H. Fröhlich, Amit Sharma, J. Oldenburg, 2017, Neurobiology of Aging.

Haemophilia patients’ unmet needs and their expectations of the new extended half‐life factor concentrates

J. Oldenburg, W. Miesbach, I. Pabinger, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Coagulation activation and fibrinolysis impairment are reduced in patients with anxiety and depression when medicated with serotonergic antidepressants

J. Oldenburg, K. Imbierowicz, D. Klingmüller, 2011, Psychiatry and clinical neurosciences.

Treatment of Adults with Clinically Suspected Severe Thrombotic Thrombocytopenic Purpura – Experiences of a Single Centre

J. Oldenburg, H. Vetter, M. Bartels, 2007, Transfusion Medicine and Hemotherapy.

Vitamin K–Dependent Coagulation Factors Deficiency

J. Oldenburg, M. Watzka, B. Brenner, 2009, Seminars in thrombosis and hemostasis.

Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.

A. Ziegler, J. Schramm, A. Boström, 2006, Journal of neurosurgery.

Pharmacokinetics of a novel extended half‐life glycoPEGylated factor IX, nonacog beta pegol (N9‐GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials

J. Oldenburg, E. Santagostino, M. Carcao, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

P. Giangrande, J. Oldenburg, E. Santagostino, 2016, Thrombosis and Haemostasis.

Detectable SARS-CoV-2 RNAemia in Critically Ill Patients, but Not in Mild and Asymptomatic Infections

C. Putensen, G. Hartmann, J. Oldenburg, 2021, Transfusion Medicine and Hemotherapy.

Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A

J. Oldenburg, J. Mahlangu, R. Klamroth, 2016, Thrombosis and Haemostasis.

Perioperative management and outcome of fracture treatment in patients with haemophilia without inhibitors

C. Burger, J. Oldenburg, M. Friedrich, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

This information is current as in Human B Cells and Monocytes RII ε Distinct Expression and Function of Fc Garbi

J. Oldenburg, M. Sylvester, N. Novak, 2017 .

Distinct Expression and Function of FcεRII in Human B Cells and Monocytes

J. Oldenburg, M. Sylvester, N. Novak, 2017, The Journal of Immunology.

Vitamin K Epoxide Reductase Complex Subunit 1-Like 1 (VKORC1L1) Inhibition Induces a Proliferative and Pro-inflammatory Vascular Smooth Muscle Cell Phenotype

J. Oldenburg, S. Zimmer, G. Nickenig, 2021, Frontiers in Cardiovascular Medicine.

Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation

P. Reitsma, M. Neumaier, P. Corbisier, 2005, Clinical chemistry and laboratory medicine.

Genetic testing in bleeding disorders

J. Oldenburg, O. el-Maarri, D. Perry, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity

W. Wels, J. Oldenburg, P. Brossart, 2022, Frontiers in Immunology.

Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A

C. Königs, J. Oldenburg, C. Escuriola-Ettingshausen, 2020, Hämostaseologie.

Protamine-adsorbed magnetic nanoparticles for efficient isolation and concentration of hepatitis-C virus from human plasma samples.

J. Oldenburg, G. Mayer, Jens Müller, 2014, Chemical communications.

First report of a FVII-deficient Indian patient carrying double heterozygous mutations in the FVII gene.

E. Seifried, A. Biswas, J. Oldenburg, 2005, Thrombosis research.

Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection

U. Spengler, E. Bierhoff, J. Oldenburg, 1997, Virchows Archiv.

Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence

G. Lüchters, J. Nattermann, M. Vogel, 2011, European journal of medical research.

Elevated Interleukin-6 Concentration and Alterations of the Coagulation System Are Associated with the Development of Intraventricular Hemorrhage in Extremely Preterm Infants

J. Oldenburg, P. Bartmann, A. Müller, 2012, Neonatology.

The coagulation system of extremely preterm infants: influence of perinatal risk factors on coagulation

J. Oldenburg, P. Bartmann, A. Heep, 2012, Journal of Perinatology.

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

J. Oldenburg, A. Pavlova, A. Hochhaus, 2007, Blood.

Coagulation Factor XIIIA Subunit Missense Mutations Affect Structure and Function at the Various Steps of Factor XIII Action

A. Biswas, J. Oldenburg, J. Dodt, 2016, Human mutation.

NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation

M. Essler, Amit Sharma, J. Oldenburg, 2021, Frontiers in Immunology.

Genetic markers in acquired haemophilia

J. Oldenburg, A. Pavlova, H. Zeitler, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

DNA methylation signature in peripheral blood reveals distinct characteristics of human X chromosome numerical aberrations

M. Nöthen, H. Fröhlich, P. Hoffmann, 2015, Clinical Epigenetics.

Exploring Diverse Coagulation Factor XIII Subunit Expression Datasets: A Bioinformatic Analysis

A. Biswas, M. Jamil, J. Oldenburg, 2022, International journal of molecular sciences.

Missense mutations at ALA‐10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy

J. Oldenburg, W. Kress, A. Fregin, 1997, British journal of haematology.

Variants in FIX propeptide associated with vitamin K antagonist hypersensitivity: functional analysis and additional data confirming the common founder mutations

J. Oldenburg, A. Pavlova, S. Ulrich, 2018, Annals of Hematology.

Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle.

J. Oldenburg, M. Watzka, C. Bevans, 2006, Antioxidants & redox signaling.

Spleen Size and Thrombocytopenia After Transcatheter Aortic Valve Implantation.

J. Oldenburg, S. Zimmer, G. Nickenig, 2021, The American journal of cardiology.

An update of the mutation profile of Factor 13 A and B genes.

A. Biswas, J. Oldenburg, V. Ivaškevičius, 2011, Blood reviews.

Exploring the structural similarity yet functional distinction between coagulation factor XIII-B and complement factor H sushi domains

A. Biswas, J. Oldenburg, Sneha Singh, 2019, Journal of Thrombosis and Thrombolysis.

Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort

M. Vogel, J. Rockstroh, T. Sauerbruch, 2007, AIDS.

Prevalence of Obesity in Young Patients with Severe Haemophilia and Its Potential Impact on Factor VIII Consumption in Germany

C. Königs, J. Oldenburg, K. Kurnik, 2019, Hämostaseologie.

Once‐weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9‐GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials

J. Oldenburg, M. Carcao, C. Négrier, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Identification of Potential Novel Interacting Partners for Coagulation Factor XIII B (FXIII-B) Subunit, a Protein Associated with a Rare Bleeding Disorder

Christoph A. Krettler, P. Volkers, A. Biswas, 2019, International journal of molecular sciences.

Patient Blood Management is Associated With a Substantial Reduction of Red Blood Cell Utilization and Safe for Patient's Outcome: A Prospective, Multicenter Cohort Study With a Noninferiority Design

P. Meybohm, E. Seifried, J. Renner, 2016, Annals of surgery.

Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR‐L interaction, IL‐10 and TGF‐β

A. Hoerauf, J. Oldenburg, J. Satoguina, 2008, European journal of immunology.

Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter

S. Kaveri, S. Lacroix-Desmazes, J. Dimitrov, 2013, Haematologica.

Transcatheter aortic valve implantation leads to a restoration of von Willebrand factor (VWF) abnormalities in patients with severe aortic stenosis - Incidence and relevance of clinical and subclinical VWF dysfunction in patients undergoing transfemoral TAVI.

J. Oldenburg, G. Nickenig, J. Driesen, 2017, Thrombosis research.

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference

J. Astermark, J. Oldenburg, C. Leissinger, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

HLA genotype in patients with acquired haemophilia A

J. Oldenburg, A. Pavlova, H. Brackmann, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

HLA Profile in Acquired Hemophilia

E. Seifried, J. Oldenburg, A. Pavlova, 2005 .

Inhibitor development in correlation to factor VIII genotypes

J. Oldenburg, O. el-Maarri, R. Schwaab, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Blood Coagulation , Fibrinolysis and Cellular Haemostasis Molecular basis of antithrombin deficiency

E. Seifried, J. Oldenburg, D. Delev, 2018 .

Factor 5 mutation profile in German patients with homozygous and heterozygous factor V deficiency

E. Seifried, J. Oldenburg, D. Delev, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

γAla82Gly represents a common fibrinogen γ-chain variant in Caucasians

T. Wienker, E. Seifried, J. Oldenburg, 2005 .

gammaAla82Gly represents a common fibrinogen gamma-chain variant in Caucasians.

T. Wienker, E. Seifried, J. Oldenburg, 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Impact of interleukin 6 promoter polymorphisms (−174 G > C, −572 G > C and −597 G > A) on plasma IL-6 levels and their influence on the development of DVT: a study from India

A. Biswas, J. Oldenburg, Kanwaljeet Singh, 2018, Hematology.

Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement

A. Iorio, E. Iserman, J. Oldenburg, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH

J. Oldenburg, W. Korte, A. Greinacher, 2021, Hämostaseologie.

Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland

L. Alberio, J. Oldenburg, P. Knöbl, 2009, Annals of Hematology.

Prophylaxis in bleeding disorders.

J. Oldenburg, 2011, Thrombosis research.

A critical appraisal of one‐stage and chromogenic assays of factor VIII activity

J. Oldenburg, K. Friedman, F. Peyvandi, 2016, Journal of thrombosis and haemostasis : JTH.

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.

J. Oldenburg, T. Klingebiel, C. E. Ettingshausen, 2002, Seminars in thrombosis and hemostasis.

Induction of Immune Tolerance in Haemophilia A Inhibitor Patients by the ‘Bonn Protocol’: Predictive Parameter for Therapy Duration and Outcome

J. Oldenburg, R. Schwaab, H. Brackmann, 1999, Vox Sanguinis.

Immune Tolerance for the Treatment of Factor VIII Inhibitors ‐ Twenty Years' ‘Bonn Protocol’

J. Oldenburg, R. Schwaab, H. Brackmann, 1996, Vox sanguinis.

The role of variant alleles of the mannose-binding lectin in the inhibitor development in severe hemophilia A.

J. Oldenburg, A. Pavlova, G. Ulrich-Merzenich, 2019, Thrombosis research.

Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens.

J. Oldenburg, 2015, Blood.

Novel products for haemostasis – current status

J. Oldenburg, T. Albert, Johannes Oldenburg, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART

F. Lammert, J. Rockstroh, T. Sauerbruch, 2010, European Journal of Medical Research.

Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART.

F. Lammert, T. Sauerbruch, U. Spengler, 2009, European journal of medical research.

Inhibitor development and management in three non-severe haemophilia A patients with T295A variant.

J. Oldenburg, V. Ivaškevičius, C. Klein, 2014, Hamostaseologie.

Molecular mechanisms underlying hemophilia A phenotype in seven females

J. Oldenburg, A. Pavlova, A. Srivastava, 2009, Journal of thrombosis and haemostasis : JTH.

Inhibitor Development in Patients with Hemophilia A after Continuous Infusion of FVIII Concentrates

J. Oldenburg, K. Kurnik, M. Depka, 2005, Annals of the New York Academy of Sciences.

Characterization of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs

J. Oldenburg, R. Schwaab, K. Olek, 1995, British journal of haematology.

Erratum: Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH

J. Oldenburg, W. Korte, A. Greinacher, 2021, Hämostaseologie.

The Role of GRP and MGP in the Development of Non-Hemorrhagic VKCFD1 Phenotypes

J. Oldenburg, Suvoshree Ghosh, Katrin J Czogalla-Nitsche, 2022, International journal of molecular sciences.

Treatment of the antiphospholipid syndrome with direct oral anticoagulantsPosition statement of German societies.

J. Oldenburg, S. Schellong, M. Stücker, 2019, VASA. Zeitschrift fur Gefasskrankheiten.

Increased Prevalence of Elevated D-Dimer Levels in Patients on Direct Oral Anticoagulants: Results of a Large Retrospective Study

J. Oldenburg, Jens Müller, N. S. Hamedani, 2022, Frontiers in Cardiovascular Medicine.

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study

J. Oldenburg, M. Ozelo, M. Trossaërt, 2021, Journal of Clinical Medicine.

Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural)

J. Astermark, J. Oldenburg, C. Kempton, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

NLRP7 inter-domain interactions: the NACHT-associated domain is the physical mediator for oligomeric assembly.

A. Biswas, H. Singer, J. Oldenburg, 2014, Molecular human reproduction.

Blood Coagulation, Fibrinolysis and Cellular Haemostasis Deficiencies of antithrombin, protein C and protein S – Practical experience in genetic analysis of a large patient cohort

J. Oldenburg, A. Pavlova, J. Driesen, 2017 .

Inhibitory oligodeoxynucleotides downregulate herpes simplex virus-induced plasmacytoid dendritic cell type I interferon production and modulate cell function.

T. Bieber, J. Oldenburg, N. Novak, 2007, Human immunology.

Prosthetic heart valves and rare hypersensitivity to vitamin K antagonists resulting from factor IX mutation: how to manage anticoagulation?

J. Oldenburg, A. Holbro, T. Tran, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Turoctocog alfa (recombinant factor VIII)

J. Oldenburg, R. Klamroth, A. Tiede, 2015, Hämostaseologie.

NovoSeven® in immune tolerance therapy

J. Oldenburg, R. Schwaab, H. Brackmann, 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Association between Anxiety and Factors of Coagulation and Fibrinolysis

J. Oldenburg, K. Imbierowicz, F. Geiser, 2008, Psychotherapy and Psychosomatics.

Bleeding and non-bleeding phenotypes in patients with GGCX gene mutations.

J. Oldenburg, T. Dörner, C. Geisen, 2014, Thrombosis research.

Comparative genetics of warfarin resistance

J. Oldenburg, S. Rost, M. Watzka, 2013, Hämostaseologie.

Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces.

A. Biswas, J. Oldenburg, K. Czogalla, 2013, Blood.

interfaces 4-hydroxycoumarin resistance and affect putative warfarin binding Human VKORC1 mutations cause variable degrees of

A. Biswas, J. Oldenburg, K. Czogalla, 2013 .

THROMBOSIS AND HEMOSTASIS Human VKORC 1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces

A. Biswas, J. Oldenburg, K. Czogalla, 2013 .

VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding

E. Seifried, J. Oldenburg, M. Paulsson, 2009, Thrombosis and Haemostasis.

VKORC1: the little big protein

J. Oldenburg, 2005 .

Sequence of the rat factor VIII cDNA.

E. Seifried, J. Oldenburg, C. Geisen, 2003, Thrombosis and haemostasis.

Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII protein

J. Oldenburg, K. Michaelides, R. Schwaab, 1997, Human Genetics.

Hemophilia A Patients with Undetectable Mutations: Current Knowledge and Future Directions*

J. Oldenburg, O. el-Maarri, H. Brackmann, 2006, Transfusion Medicine and Hemotherapy.

Haemophilia A: from mutation analysis to new therapies

J. Oldenburg, M. Spannagl, R. Schwaab, 2005, Nature Reviews Genetics.

Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rsI2979860 polymorphism of the IL28B gene

F. Lammert, H. Nischalke, T. Sauerbruch, 2011, European journal of medical research.

Characterization of a novel large deletion caused by double-stranded breaks in 6-bp microhomologous sequences of intron 11 and 12 of the F13A1 gene

A. Biswas, J. Oldenburg, J. Goudemand, 2016, Human Genome Variation.

Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene

J. Oldenburg, O. el-Maarri, A. Terzić, 2005, Journal of thrombosis and haemostasis : JTH.

Recurrent intracardiac thrombosis as an unusual manifestation of inherited thrombophilia.

J. Oldenburg, B. Pötzsch, Jens Mueller, 2007, International journal of cardiology.

Treatment of acute pulmonary haemorrhage in extremely preterm infants with recombinant activated factor VII

J. Oldenburg, P. Bartmann, A. Müller, 2009, Acta paediatrica.

Neoplasm-induced bleeding in inherited, heterozygous FXIII-A deficiency

A. Biswas, J. Oldenburg, V. Ivaškevičius, 2015, Hämostaseologie.

Eight novel F13A1 gene missense mutations in patients with mild FXIII deficiency: in silico analysis suggests changes in FXIII-A subunit structure/function

A. Biswas, J. Oldenburg, V. Ivaškevičius, 2014, Annals of Hematology.

Five Novel Mutations in F13B Gene Resulting in Mild FXIII Deficiency

E. Seifried, J. Oldenburg, V. Ivaškevičius, 2007 .

Establishment of an International Registry of Patients with Congenital FXIII Deficiency

E. Seifried, J. Oldenburg, V. Ivaškevičius, 2007 .

International Registry on Factor XIII Deficiency: A basis formed mostly on European data

E. Seifried, J. Oldenburg, V. Ivaškevičius, 2007, Thrombosis and Haemostasis.

Coagulation Factor XIII Mutation Profile: Update 2004

E. Seifried, J. Oldenburg, V. Ivaškevičius, 2006 .

Combined Heterozygous Factor XIII-Deficiency in a Family Case Report

J. Oldenburg, V. Ivaškevičius, C. E. Ettingshausen, 2005 .

Coagulation factor XIII deficiency

A. Biswas, J. Oldenburg, V. Ivaškevičius, 2014, Hämostaseologie.

Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency

A. Biswas, J. Oldenburg, V. Ivaškevičius, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Congenital hypersensitivity to vitamin K antagonists due to FIX propeptide mutation at locus -10: a (not so) rare cause of bleeding under oral anticoagulant therapy in Switzerland.

R. Speich, J. Oldenburg, S. Ulrich, 2008, Swiss medical weekly.

Genomics of bleeding disorders

J. Oldenburg, A. Pavlova, A. Goodeve, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Philadelphia-positive acute lymphoblastic leukemia ( Ph imatinib-based therapy and give rise to relapse in patients with de novo Kinase domain mutations of BCR-ABL frequently precede

J. Oldenburg, A. Pavlova, A. Hochhaus, 2007 .

Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?

J. Oldenburg, R. Schwaab, H. Brackmann, 1998, European journal of haematology. Supplementum.

Increased circulating levels of neurotrophins and elevated expression of their high-affinity receptors on skin and gut mast cells in mastocytosis.

R. Fimmers, E. Wardelmann, Wei Zhao, 2013, Blood.

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS Increased circulating levels of neurotrophins and elevated expression of their high-af ﬁ nity receptors on skin and gut mast cells in mastocytosis

R. Fimmers, E. Wardelmann, J. Oldenburg, 2013 .

Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV.

T. Sauerbruch, U. Spengler, E. Bierhoff, 1996, The American journal of gastroenterology.

Maternal alleles acquiring paternal methylation patterns in biparental complete hydatidiform moles.

M. Seoud, G. Rouleau, J. Oldenburg, 2003, Human molecular genetics.

Pseudo-Homozygous APC Resistance Due to Coinheritance of Heterozygous Factor V — R506Q and Type I Deficiency Associated with Thrombosis

J. Oldenburg, D. Delev, A. Pavlova, 2008 .

Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF‐containing plasma‐derived FVIII concentrate

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Identification and functional characterization of a novel F5 mutation (Ala512Val, FVBonn) associated with activated protein C resistance

A. Biswas, J. Oldenburg, A. Pavlova, 2016, Journal of thrombosis and haemostasis : JTH.

Estimation of Nuwiq® (simoctocog alfa) activity using one‐stage and chromogenic assays—Results from an international comparative field study

J. Oldenburg, T. Vicente, U. Scholz, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Defining Severity of Hemophilia: More than Factor Levels

J. Oldenburg, A. Pavlova, 2013, Seminars in Thrombosis & Hemostasis.

Determination of the warfarin inhibition constant Ki for vitamin K 2,3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assay.

Christoph A. Krettler, J. Oldenburg, M. Watzka, 2013, Biochimica et biophysica acta.

The relevance of the bleeding severity in the treatment of acquired haemophilia – an update of a single‐centre experience with 67 patients

J. Oldenburg, H. Brackmann, G. Ulrich-Merzenich, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Genetic landscape in coagulation factor XIII associated defects - Advances in coagulation and beyond.

A. Biswas, J. Oldenburg, Sneha Singh, 2022, Blood reviews.

Acute hepatitis A in haemophiliacs

J. Oldenburg, W. Gerlich, H. Brackmann, 1992, The Lancet.

The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH

J. Oldenburg, M. Makris, G. Castaman, 2018, Journal of thrombosis and haemostasis : JTH.

Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype

J. Oldenburg, A. Pavlova, 2010, Hämostaseologie.

Genetic risk factors for inhibitors to factors VIII and IX

J. Oldenburg, A. Pavlova, A. Pavlova, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

A novel fibrinogen γ chain frameshift deletion (c.637delT) in a patient with hypodysfibrinogenemia associated with thrombosis.

A. Biswas, J. Oldenburg, A. Pavlova, 2015, Hamostaseologie.

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab

J. Oldenburg, E. Santagostino, M. Carcao, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Immunoadsorption in the treatment of acquired haemophilia.

J. Oldenburg, H. Brackmann, G. Ulrich-Merzenich, 2009, Atherosclerosis. Supplements.

Large deletions identified in patients with von Willebrand disease using multiple ligation‐dependent probe amplification

J. Oldenburg, A. Pavlova, J. Driesen, 2011, Journal of thrombosis and haemostasis : JTH.

Co-activation through TLR4 and TLR9 but not TLR2 skews Treg-mediated modulation of Igs and induces IL-17 secretion in Treg:B cell co-cultures

A. Hoerauf, J. Oldenburg, J. Satoguina, 2014, Innate immunity.

The B-cell epitope of the monoclonal anti-factor VIII antibody ESH8 characterized by peptide array analysis

J. Oldenburg, R. Schwaab, T. Albert, 2008, Thrombosis and Haemostasis.

Alternative Therapy such as the Acupuncture of the Skull for Hemophilic Arthropathy

T. Wallny, J. Oldenburg, H. Brackmann, 2007 .

Successful pain treatment in arthropathic lower extremities by acupuncture in haemophilia patients

T. Wallny, J. Oldenburg, H. Brackmann, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis

J. Oldenburg, L. Afrin, G. Molderings, 2021, International journal of molecular sciences.

First Case of Compound Heterozygous Mutations in the Kininogen Gene Causing Severe High Molecular Weight Kininogen Deficiency

E. Seifried, J. Oldenburg, C. Geisen, 2005 .

Acquired deficiency of coagulation factor XIII—possible evidence for a new link between coagulation and infection from a case

J. Oldenburg, W. Ludwig, D. Peetz, 2013, Annals of Hematology.

In silico calculated affinity of FVIII‐derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene

S. Kaveri, S. Lacroix-Desmazes, J. Oldenburg, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Founder mutation Arg485Pro led to recurrent compound heterozygous GGCX genotypes in two German patients with VKCFD type 1

E. Seifried, J. Oldenburg, C. Geisen, 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Compound heterozygous mutations in the γ‐glutamyl carboxylase gene cause combined deficiency of all vitamin K‐dependent blood coagulation factors

J. Oldenburg, A. Fregin, S. Rost, 2004, British journal of haematology.

Disruption of Structural Disulfides of Coagulation FXIII-B Subunit; Functional Implications for a Rare Bleeding Disorder

A. Biswas, J. Oldenburg, Sneha Singh, 2019, International journal of molecular sciences.

Label-Free Kinetic Studies of Hemostasis-Related Biomarkers Including D-Dimer Using Autologous Serum Transfusion

J. Oldenburg, Jens Müller, B. Pötzsch, 2015, PloS one.

PC Deficiency Testing: Thrombin-Thrombomodulin as PC Activator and Aptamer-Based Enzyme Capturing Increase Diagnostic Accuracy

J. Oldenburg, A. Pavlova, Jens Müller, 2021, Frontiers in Cardiovascular Medicine.

Congenital combined deficiency of coagulation factors VII and X – different genetic mechanisms

J. Oldenburg, A. Pavlova, J. Driesen, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Molecular analysis of FVIII gene in severe HA patients of Costa Rica.

J. Oldenburg, A. Pavlova, K. Wulff, 2010, Hamostaseologie.

Molecular genetic background of haemophilia A patients with discrepancy between one-stage and two-stage factor VIII assays

J. Oldenburg, D. Delev, A. Pavlova, 2010 .

Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program

J. Oldenburg, C. Kessler, R. Klamroth, 2019, Therapeutic advances in hematology.

New images in haemophilia

J. Oldenburg, E. Mauser-Bunschoten, E. Mauser-Bunschoten, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Effects of the CCR5-Δ32 Mutation on Hepatitis C Virus-Specific Immune Responses in Patients with Haemophilia

G. Feldmann, G. Ahlenstiel, J. Nattermann, 2009, Immunological investigations.

Search for intrafamilial transmission of hepatitis C virus in hemophilia patients.

J. Oldenburg, H. Brackmann, K. Schneweis, 1993, Blood.

Polymorphisms in the CTLA‐4 gene and inhibitor development in patients with severe hemophilia A

J. Astermark, J. Oldenburg, A. Lefvert, 2007, Journal of thrombosis and haemostasis : JTH.

High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11.

K. Strauch, M. Mattheisen, H. Bickeböller, 2005, Blood.

Porphyromonas gingivalis Outer Membrane Vesicles Induce Selective Tumor Necrosis Factor Tolerance in a Toll-Like Receptor 4- and mTOR-Dependent Manner

A. Hoerauf, J. Deschner, J. Oldenburg, 2016, Infection and Immunity.

A Validated HPLC Method for the Determination of Vitamin K in Human Serum – First Application in a Pharmacological Study

J. Oldenburg, M. Watzka, D. Lütjohann, 2011 .

Severe bleeding in two patients due to increased sensitivity of factor IX activity to phenprocoumon therapy

J. Oldenburg, H. Hertfelder, E. Quenzel, 1997, Annals of Hematology.

γA1a82Gly Represents a Common Fibrinogen Chain Variant in Caucasians

T. Wienker, E. Seifried, J. Oldenburg, 2006 .

Long Term Optimisation of F8 Gene Mutation Screening by DHPLC

E. Seifried, H. Singer, J. Oldenburg, 2005 .

Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients.

J. Nattermann, J. Rockstroh, U. Spengler, 2009, Clinical science.

New Insight into the Molecular Basis of Hemophilia A

J. Oldenburg, O. el-Maarri, 2006, International journal of hematology.

Evaluation of Denaturing High Performance Liquid Chromatography (DHPLC) in the Analysis of Hemophilia A

J. Oldenburg, O. el-Maarri, S. Rost, 2002 .

Genotype-Phenotype Correlation in Hemophilia A

J. Oldenburg, R. Schwaab, W. Schramm, 2001 .

IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data

J. Oldenburg, C. Hermans, C. Leissinger, 2022, Journal of clinical medicine.

Low‐titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half‐life after immune tolerance induction

J. Oldenburg, W. V. van Heerde, B. Verbruggen, 2012, Journal of thrombosis and haemostasis : JTH.

Functional Characterization of Antithrombin Mutations by Monitoring of Thrombin Inhibition Kinetics

J. Oldenburg, A. Pavlova, B. Pezeshkpoor, 2021, International journal of molecular sciences.

Molecular characterization of mild-to-moderate hemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis.

S. Antonarakis, H. Kazazian, J. Oldenburg, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers but not of Prothrombin 20210G>A Carriers.

J. Oldenburg, Jens Müller, B. Pötzsch, 2019, Circulation research.

Mutations in the VKORC1 Gene Cause Warfarin Resistance, Warfarin Sensitivity and Combined Deficiency of Vitamin K Dependent Coagulation Factors.

E. Seifried, J. Oldenburg, C. Geisen, 2004 .

The problem of novel FVIII missense mutations for haemophilia A genetic counseling.

J. Oldenburg, R. Schneppenheim, T. Obser, 2009, Hamostaseologie.

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein

J. Dumont, J. Oldenburg, V. Blanchette, 2018, Haemophilia.

European retrospective study of real‐life haemophilia treatment

J. Oldenburg, C. Hermans, G. Dolan, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study

E. Neufeld, J. Oldenburg, V. Jiménez‐Yuste, 2021, Thrombosis and Haemostasis.

Determination of Plasma Heparin Level Improves Identification of Systemic Mast Cell Activation Disease

J. Oldenburg, G. Molderings, H. Hertfelder, 2015, PloS one.

NLRP7, Involved in Hydatidiform Molar Pregnancy (HYDM1), Interacts with the Transcriptional Repressor ZBTB16

A. Biswas, H. Singer, J. Oldenburg, 2015, PloS one.

NLRP 7 , Involved in Hydatidiform Molar Pregnancy ( HYDM 1 ) , Interacts with the Transcriptional Repressor ZBTB 16

A. Biswas, H. Singer, J. Oldenburg, 2015 .

An Alu repeat-mediated genomic GCNT2 deletion underlies congenital cataracts and adult i blood group

J. Oldenburg, G. Nürnberg, P. Nürnberg, 2012, Human Genetics.

Factor VIII intron‐1 inversion: frequency and inhibitor prevalence

J. Oldenburg, O. el-Maarri, R. Schwaab, 2006, Journal of thrombosis and haemostasis : JTH.

Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors

J. Oldenburg, C. Négrier, W. Schramm, 2020, Hämostaseologie.

Acute Hepatitis E Virus infection in a hemophilic patient with acquired inhibitor during immune tolerance therapy according to modified Bonn‐Malmö protocol

U. Spengler, J. Oldenburg, A. Eis-Hübinger, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment of minor severe acquired haemophilia. Is there a rationale for immunoadsorption?

J. Oldenburg, H. Zeitler, G. Goldmann, 2015, Atherosclerosis. Supplements.

Immunoadsorption for Pregnancy‐Associated Severe Acquired Hemophilia

J. Oldenburg, G. Ulrich-Merzenich, H. Zeitler, 2014, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

Extracorporeal Treatment for the Acute und Long-Term Outcome of Patients with Life-Threatening Acquired Hemophilia

J. Oldenburg, H. Brackmann, G. Ulrich-Merzenich, 2012, Transfusion Medicine and Hemotherapy.

Treatment of Factor VIII Inhibitors with Selective IgG Immunoadsorption – a Single Center Experience in 50 Patients with Acquired Hemophilia*

J. Oldenburg, H. Vetter, H. Brackmann, 2006, Transfusion Medicine and Hemotherapy.

Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies.

J. Oldenburg, V. Jiménez‐Yuste, S. Chebon, 2020, Blood.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

J. Oldenburg, V. Jiménez‐Yuste, C. Kempton, 2018, The New England journal of medicine.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

J. Oldenburg, E. Santagostino, C. Kessler, 2017, The New England journal of medicine.

MALDI Imaging of predictive ferritin, fibrinogen and proteases in haemophilic arthropathy

R. Casadonte, M. Kriegsmann, M. Otto, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.

J. Oldenburg, F. Horling, H. Schwarz, 2013, Blood.

Maximum foot pressure during gait in patients with severe haemophilia: A controlled cross-sectional study

S. Koob, J. Oldenburg, F. Schildberg, 2022, Gait & Posture.

Changes of static and dynamic spine alignment in patients with severe haemophilia

J. Oldenburg, D. Wirtz, T. Hilberg, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment options for haemophilic arthropathy of the elbow after failed conservative therapy. A single centre experience.

J. Oldenburg, S. Ezziddin, R. Pflugmacher, 2014, Hamostaseologie.

Prophylaxis in adult patients with severe haemophilia A.

J. Oldenburg, H. Brackmann, 2014, Thrombosis research.

Safety and efficacy of BAY 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme

J. Oldenburg, J. Windyga, S. Lalezari, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical and patient reported outcome in total ankle replacement compared to ankle fusion in end‐stage haemophilic arthropathy

M. Kehrer, J. Oldenburg, D. Wirtz, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Radiosynoviorthesis in hemophilic arthropathy: pathologic blood pool imaging on pre-therapeutic bone scintigraphy is not a predictor of treatment success

J. Oldenburg, H. Biersack, S. Ezziddin, 2016, European Journal of Nuclear Medicine and Molecular Imaging.

Outcome after total knee arthroplasty in haemophilic patients with stiff knees

J. Oldenburg, R. Pflugmacher, M. Müller, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Total ankle replacement in patients with haemophilia and virus infections – a safe alternative to ankle arthrodesis?

J. Oldenburg, M. Wessling, M. Wimmer, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience.

J. Oldenburg, H. Brackmann, U. Hammerstein, 1992, Haemostasis.

Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand

J. Oldenburg, E. Zanon, R. Zimmermann, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Elective total knee arthroplasty in haemophilic patients. Proposal for a clinical pathway.

T. Wallny, J. Oldenburg, D. Wirtz, 2014, Hamostaseologie.

Successful angiographic embolization of recurrent elbow and knee joint bleeds in seven patients with severe haemophilia

J. Oldenburg, R. Klamroth, S. Gottstein, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[Impact of Preoperative Knee Stiffness on the Postoperative Outcome after Total Knee Arthroplasty in Patients with Haemophilia].

J. Oldenburg, D. Wirtz, R. Placzek, 2015, Zeitschrift fur Orthopadie und Unfallchirurgie.

Perioperative management and outcome of general and abdominal surgery in hemophiliacs.

T. Hoeller, J. Oldenburg, N. Schaefer, 2010, American journal of surgery.

Long‐term outcome of total hip arthroplasty in patients with haemophilia

J. Oldenburg, B. Nouri, M. Wimmer, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Falling and fall risk in adult patients with severe haemophilia.

S. Koob, J. Oldenburg, R. Bornemann, 2016, Hamostaseologie.

Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans.

J. Oldenburg, F. Horling, A. Greinacher, 2015, Blood.

A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.

J. Oldenburg, V. Jiménez‐Yuste, Michael Wang, 2019, Blood.

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

J. Oldenburg, V. Jiménez‐Yuste, A. Pavlova, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.

J. Oldenburg, G. Auerswald, R. Ljung, 2013, Blood.

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

J. Oldenburg, E. Santagostino, B. Konkle, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study

J. Epstein, G. Spotts, J. Oldenburg, 2013, Annals of Hematology.

Potential biomarkers of haemophilic arthropathy: correlations with compatible additive magnetic resonance imaging scores

J. Oldenburg, E. Zanon, R. Zimmermann, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three‐year follow‐up of the AHEAD (Advate in HaEmophilia A outcome Database) study

G. Spotts, J. Oldenburg, C. Hermans, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.

J. Oldenburg, C. Négrier, J. Mahlangu, 2014, Blood.

Rehabilitation of synovitis in patients with haemophilia

J. Oldenburg, A. Seuser, P. Berdel, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.

J. Oldenburg, C. Hermans, V. Jiménez‐Yuste, 2023, The Lancet. Haematology.

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study

J. Oldenburg, V. Jiménez‐Yuste, S. Lethagen, 2019, BMJ Open.

Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.

J. Oldenburg, D. Perry, M. Ozelo, 2016, Thrombosis and haemostasis.

Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein ( rFIXFc ) in subjects with haemophilia

J. Oldenburg, D. Perry, M. Ozelo, 2017 .

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

J. Oldenburg, V. Jiménez‐Yuste, S. Chebon, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[Hemophiliac arthropathy of the knee joint. Gd-DTPA-enhanced MRI; clinical and roentgenological correlation].

M. Reiser, J. Oldenburg, A. Steudel, 1994, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

Rapid and sustained immune tolerance to inhibitors induced by a plasma‐derived, VWF‐containing FVIII concentrate

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2019, Haemophilia.

Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy

Songkai Yan, J. Oldenburg, G. Krishnarajah, 2020, Current medical research and opinion.

The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study

J. Oldenburg, E. Santagostino, C. Kessler, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice

J. Oldenburg, E. Santagostino, L. Boggio, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study

J. Oldenburg, M. Ozelo, H. Chambost, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin‐free method] demonstrates efficacy, safety and low‐risk for immunogenicity in routine clinical practice

G. Spotts, J. Oldenburg, L. Valentino, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemophilia care then, now and in the future

J. Oldenburg, G. Dolan, G. Lemm, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Urological surgery in patients with hemorrhagic bleeding disorders Hemophilia A, Hemophilia B, von Willebrand disease: a retrospective study with matched pairs analysis

J. Oldenburg, S. Hauser, S. C. Mueller, 2013, World Journal of Urology.

Long-term outcome of liver transplantation in HCV/HIV coinfected haemophilia patients. A single centre study of 10 patients.

C. Strassburg, J. Oldenburg, H. Zeitler, 2014, Hämostaseologie.

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.

J. Astermark, J. Oldenburg, A. Pavlova, 2006, Blood.

HLA Genotype of Patients with Severe Haemophilia A due to Intron 22 Inversion with and without Inhibitors of Factor VIII

J. Oldenburg, R. Schwaab, E. Tuddenham, 1997, Thrombosis and Haemostasis.

[Pseudo tumours in haemophilia patients].

O. Weber, J. Oldenburg, G. Pagenstert, 2009, Hamostaseologie.

[Backpain and haemophilia].

J. Oldenburg, A. Seuser, P. Berdel, 2008, Hämostaseologie.

Giant haemophilic pseudotumour of the pelvis: case report and literature review

J. Oldenburg, C. Klein, M. Friedrich, 2015, Haemophilia.

Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study

J. Oldenburg, C. Kempton, M. Mancuso, 2017 .

Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)

J. Oldenburg, V. Jiménez‐Yuste, M. Recht, 2017 .

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors

J. Oldenburg, J. Mahlangu, R. Liesner, 2017 .

Real World Prospective Data on Bleeding Frequency in 1,000 Patients with Hemophilia a - is the Goal of Zero Bleeds Achievable?

J. Oldenburg, K. Khair, K. Kurnik, 2017 .

Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A

J. Oldenburg, T. Lissitchkov, S. Knaub, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Association between phenotype and genotype in carriers of haemophilia A

J. Oldenburg, C. Geisen, W. Miesbach, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[Upper ankle joint prostheses in haemophilia patients].

J. Oldenburg, G. Pagenstert, S. Gravius, 2009, Hämostaseologie.

Polymorphisms in the IL-10 but not in the IL-1{beta} and IL-4 genes are associated with inhibitor development in patients with hemophilia A.

J. Astermark, J. Oldenburg, A. Pavlova, 2006 .

No increased bleeding risk for oral surgery in patients with severe congenital bleeding disorders due to intense perioperative management

J. Oldenburg, R. Reich, C. Berens, 2015, Oral and Maxillofacial Surgery.

Haemophiliac Pseudotumour – Two Case Reports of Patients with Moderate Haemophilia A

J. Oldenburg, C. Mauz-Koerholz, C. Kunze, 2009, Klinische Padiatrie.

[Significance of mutation analysis in patients with haemophilia A].

E. Seifried, J. Oldenburg, R. Schwaab, 2003, Hamostaseologie.

[Comprehensive Care Center Bonn from 1980 to 2009. Changes in the epidemiology and regional composition of the haemophilia population].

J. Oldenburg, H. Brackmann, I. Besmens, 2011, Hamostaseologie.

Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2020, Pediatric blood & cancer.

J. Oldenburg, V. Jiménez‐Yuste, S. Chebon, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non‐interventional study in a real‐world setting

J. Oldenburg, E. Santagostino, C. Kempton, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

C. Winkler, J. Astermark, B. Kessing, 2013, Blood.

F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort

M. Carrington, C. Winkler, J. Astermark, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary

J. Oldenburg, A. Tiede, S. Bonanad, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[Prophylactic factor substitution in severe haemophilia A. Economic assessment in adult patients].

J. Oldenburg, W. Schramm, A. Tiede, 2014, Hamostaseologie.

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results.

J. Astermark, J. Oldenburg, V. Jiménez‐Yuste, 2019, Blood.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

J. Oldenburg, G. Levy, 2017, The New England journal of medicine.

Familial Multiple Coagulation Factor Deficiencies (FMCFDs) in a Large Cohort of Patients—A Single-Center Experience in Genetic Diagnosis

J. Oldenburg, A. Pavlova, S. Unal, 2021, Journal of clinical medicine.

ITI choice for the optimal management of inhibitor patients – from a clinical and pharmacoeconomic perspective

J. Oldenburg, C. Kessler, S. Austin, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

In Vitro Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach.

J. Oldenburg, G. Mayer, Jens Müller, 2016, Nucleic acid therapeutics.

Efficacy and safety of BAY 81‐8973, a full‐length recombinant factor VIII: results from the LEOPOLD I trial

J. Oldenburg, K. Saxena, S. Lalezari, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemophilia B and other bleeding disorders

J. Oldenburg, S. Rost, V. Ivaškevičius, 2000 .

Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company

A. Iorio, J. Oldenburg, V. Jiménez‐Yuste, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Long‐term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma‐derived FVIII/VWF product: the long‐term ITI study

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[Flexion contracture in haemophilic knee arthropathy--10-year follow-up after hamstring release and dorsal capsulotomy].

T. Wallny, J. Oldenburg, C. Kraft, 2007, Zeitschrift fur Orthopadie und Unfallchirurgie.

Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency.

J. Oldenburg, M. Carcao, R. Tehranchi, 2010, Blood.

Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia

C. Königs, J. Oldenburg, R. Klamroth, 2021, Hämostaseologie.

Acute HIV-1 Infection in Patients with Hemophilia B Treated with β-Propiolactone-UV-lnactivated Clotting Factor

J. Oldenburg, H. Brackmann, K. Schneweis, 1990, Thrombosis and Haemostasis.

Gene Therapy for Hemophilia-Opportunities and Risks.

J. Oldenburg, R. Klamroth, W. Miesbach, 2022, Deutsches Arzteblatt international.

J. Oldenburg, J. Mahlangu, M. Mancuso, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

J. Oldenburg, L. Raffini, S. von Mackensen, 2019, Patient preference and adherence.

J. Oldenburg, M. Recht, J. Mahlangu, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

First Case of Laparoscopic Mini-Gastric Bypass for the Treatment of Morbid Obesity in Severe Haemophilia A.

J. Oldenburg, P. Lingohr, A. Plamper, 2018, Hamostaseologie.

Value and risk of laparoscopic surgery in hemophiliacs—experiences from a tertiary referral center for hemorrhagic diatheses

H. Matthaei, J. Oldenburg, P. Lingohr, 2014, Langenbeck's Archives of Surgery.

Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization

J. Oldenburg, R. Schwaab, H. Lenk, 2004, Thrombosis and Haemostasis.

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

Andreas Fregin, T. Strom, E. Seifried, 2004, Nature.

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study

J. Oldenburg, C. Négrier, J. Mahlangu, 2017 .

Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) for prophylaxis and treatment of bleeding episodes in patients with haemophilia B

J. Oldenburg, C. Négrier, J. Mahlangu, 2013 .

Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy.

H. Ehrlich, J. Oldenburg, R. Schwaab, 1998, Annals of hematology.

Phenotype – genotype correlation in eight Polish patients with inherited Factor XIII deficiency: identification of three novel mutations

E. Seifried, J. Oldenburg, V. Ivaškevičius, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A

J. Oldenburg, G. Castaman, T. Matsushita, 2021, BMJ Open.

Significance of F8 missense mutations with respect to inhibitor formation

J. Oldenburg, A. Pavlova, R. Schwaab, 2013, Thrombosis and Haemostasis.

Deep intronic ‘mutations’ cause hemophilia A: application of next generation sequencing in patients without detectable mutation in F8 cDNA

T. Haaf, J. Oldenburg, O. el-Maarri, 2013, Journal of thrombosis and haemostasis : JTH.

Clinical overview of Fanhdi/Alphanate (plasma‐derived, VWF‐containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Increased frequency of the CTLA‐4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls

T. Wienker, A. Hoerauf, J. Oldenburg, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A

J. Oldenburg, B. Konkle, K. Pasi, 2018, Blood.

Development of an inhibitor-specific questionnaire for the assessment of health-related quality of life in haemophilia patients with inhibitors (INHIB-QoL)

J. Oldenburg, K. Khair, S. Riva, 2013 .

[Muscular compartment syndrome of the forearm in a haemophilia inhibitor patient].

J. Oldenburg, S. Gravius, A. Seuser, 2008, Hamostaseologie.

XIII deficiency Recombinant factor XIII: a safe, and novel treatment for congenital factor

J. Oldenburg, M. Carcao, R. Tehranchi, 2012 .

Inhibitor Development in Previously Untreated Patients with Hemophilia A and B: A Prospective 23-Year Follow-Up

J. Oldenburg, C. E. Ettingshausen, W. Kreuz, 2001 .

Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe haemophilia A phenotype.

J. Oldenburg, R. Schwaab, H. Brackmann, 1998, Thrombosis and haemostasis.

Factor VIII gene (F8) mutation and inhibitor development in non-severe hemophilia A

J. Astermark, J. Oldenburg, C. Hermans, 2013 .

Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial

J. Oldenburg, E. Santagostino, S. Zupančić šalek, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A

A. Savic, J. Oldenburg, E. Santagostino, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Summary report of the First International Conference on inhibitors in haemophilia A.

L. Mantovani, P. Mannucci, F. Rosendaal, 2017, Blood transfusion = Trasfusione del sangue.

Real-world clinical experience of extended half-life recombinant factor VIII Fc fusion protein (rFVIIIFc) in comparison to conventional factor products in patients with severe hemophilia A

J. Oldenburg, T. Albert, G. Goldmann, 2021 .

Striving for a Bleed Free World - An Interim Analysis from the AHEAD Study

J. Oldenburg, K. Khair, K. Kurnik, 2016 .

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

J. Oldenburg, C. Hermans, V. Jiménez‐Yuste, 2021, Blood.

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

J. Oldenburg, V. Jiménez‐Yuste, Michael Wang, 2018, Blood.

Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting

J. Oldenburg, E. Santagostino, S. Chebon, 2017 .

Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management

J. Oldenburg, Jens Müller, B. Pötzsch, 2020, Hämostaseologie.

Chromogenic analysis of FIX activity in haemophilia B patients treated with nonacog beta pegol

J. Oldenburg, C. Négrier, G. Young, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

J. Oldenburg, C. Hermans, G. Castaman, 2021, Journal of thrombosis and haemostasis : JTH.

Pharmacokinetic-Guided Prophylaxis with Rurioctocog Alfa Pegol Improves Bleeding Rates over Standard Prophylaxis: Real-World Observational Data from the Ahead German Study

J. Oldenburg, C. Escuriola-Ettingshausen, K. Kurnik, 2021, Blood.

Molecular basis of haemophilia A

J. Oldenburg, E. Saenko, N. Ananyeva, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Consumption Of FVIII Concentrate During On-Demand and Prophylactic Treatment With Human-cl rhFVIII In Prospective Clinical Studies In Adult Patients With Severe Hemophilia A

J. Oldenburg, J. Bichler, A. Tiede, 2013 .

Risk factors for inhibitor development in hemophilia A.

J. Oldenburg, R. Schwaab, H. Brackmann, 2000, Haematologica.

Mutation Profiling in Haemophilia A

J. Oldenburg, 2001, Thrombosis and Haemostasis.

Coagulation Factor IX Propeptide Mutations Causing Coumarin Hypersensitivity: Identification of Female Alanine-10 Valine Heterozygotes

J. Oldenburg, F. Maly, L. Bestmann, 2001, Thrombosis and Haemostasis.

Analysis of expression kinetics and activity of a new B-domain truncated and full-length FVIII protein in three different cell lines

J. Oldenburg, W. Poller, R. Schwaab, 1999, Annals of Hematology.

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

J. Oldenburg, A. Chuansumrit, E. Santagostino, 2014 .

Inhibitors to Factor VIII—Molecular Basis

J. Oldenburg, E. Tuddenham, 2007 .

Recombinant FXIII (rFXIII-A 2 ) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency

B. Kerlin, J. Oldenburg, M. Carcao, 2018, Thrombosis and Haemostasis.

Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes

B. Kerlin, J. Oldenburg, M. Carcao, 2016, Seminars in Thrombosis and Hemostasis.

Methylation levels at selected CpG sites in the factor VIII and FGFR3 genes, in mature female and male germ cells: implications for male-driven evolution.

J. Walter, M. Montag, J. Oldenburg, 1998, American journal of human genetics.

Therapy-resistant haemarthros in a patient with factor VIII inhibitor: successful treatment with recombinant factor VIIa

J. Oldenburg, W. Kreuz, S. Eber, 1999, European Journal of Pediatrics.

Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A

J. Oldenburg, M. Ozelo, D. Quon, 2022, Human gene therapy.

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

J. Astermark, J. Oldenburg, G. Benson, 2019, Blood.

Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

J. Oldenburg, V. Jiménez‐Yuste, S. Chebon, 2018, Blood.

A Cross-sectional Analysis of Treatment in PUPs in 2021 in Germany – First Data from the GEPHARD Study Group

C. Königs, W. Behnisch, J. Oldenburg, 2021, Hämostaseologie.

Erratum: A Cross-sectional Analysis of Treatment in PUPs in 2021 in Germany – First Data from the GEPHARD Study Group

C. Königs, W. Behnisch, J. Oldenburg, 2021, Hämostaseologie.

Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice

J. Oldenburg, A. Pavlova, B. Pezeshkpoor, 2022, Hämostaseologie.

B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B

J. Oldenburg, K. Pasi, K. Fischer, 2018, Blood.

Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII

J. Oldenburg, A. Ganguly, V. Ivaškevičius, 2006, Thrombosis and Haemostasis.

Hepatitis A Virus Infection among the Hemophilia Population at the Bonn Hemophilia Center

J. Oldenburg, H. Brackmann, A. Eis-Hübinger, 1994, Vox sanguinis.

Acute Hepatitis C in Haemophiliacs Due to “Virus-Inactivated” Clotting Factor Concentrates

R. Kaiser, J. Oldenburg, H. Brackmann, 1992, Thrombosis and Haemostasis.

Haemophilia A: Carrier detection by DNA analysis

J. Oldenburg, R. Schwaab, H. Brackmann, 1988, Blut.

De novo factor VIII gene intron 22 inversion in a female carrier presents as a somatic mosaicism.

J. Oldenburg, O. el-Maarri, S. Rost, 2000, Blood.

Direct and indirect estimation of the sex ratio of mutation frequencies in hemophilia A.

K. Zerres, J. Oldenburg, R. Schwaab, 1993, American journal of human genetics.

Direct andIndirect Estimation oftheSexRatioofMutation Frequencies inHemophilia A

K. Zerres, J. Oldenburg, R. Schwaab, 1993 .

AHEAD. Advate in HaEmophilia A outcome Database.

J. Oldenburg, K. Kurnik, R. Klamroth, 2010, Hamostaseologie.

Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients

A. Biswas, J. Oldenburg, A. Pavlova, 2012, Thrombosis and Haemostasis.

Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study

P. Mannucci, J. Oldenburg, M. Morfini, 2020, Journal of thrombosis and haemostasis : JTH.

Type‐3 von Willebrand disease in India—Clinical spectrum and molecular profile

B. George, A. Viswabandya, A. Biswas, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[Immune tolerance therapy for inhibitors in haemophilia A].

J. Oldenburg, 2008, Hamostaseologie.

Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16.

J. Oldenburg, A. Fregin, S. Rost, 2002, Blood.

Intron 22‐specific long PCR for the Xba I polymorphism in the factor VIII gene

J. Oldenburg, O. el-Maarri, S. H. Çağlayan, 1999, British journal of haematology.

Novel findings in two patients with late‐diagnosed afibrinogenaemia: intraosseous haemorrhage and fingertip necrosis

J. Heiss, J. Oldenburg, I. Hainmann, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors in haemophilia: pathophysiology

S. Lacroix-Desmazes, J. Oldenburg, J. Saint-Remy, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A

V. Ramanan, F. Rosendaal, S. Kaveri, 2019, Haematologica.

[Characterization of factor VIII antibody epitopes from haemophilia A patients using cellulose bound FVIII peptide libraries].

J. Oldenburg, R. Schwaab, W. Schramm, 2003, Hamostaseologie.

Historical Review on Genetic Analysis in Hemophilia A

J. Oldenburg, A. Pavlova, B. Pezeshkpoor, 2014, Seminars in Thrombosis & Hemostasis.

Malignant disease in the haemophilic population: moving towards a management consensus?

J. Astermark, J. Oldenburg, M. Makris, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemophilia A in a female caused by coincidence of a Swyer syndrome and a missense mutation in factor VIII gene.

J. Oldenburg, O. el-Maarri, F. Herrmann, 2006, Thrombosis and haemostasis.

Identification of a novel factor X deletion in combination with a missense mutation in the F10 gene

J. Oldenburg, I. Hainmann, A. Pavlova, 2009, Hämostaseologie.

Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates

J. Oldenburg, S. Modrow, A. Eis-Hübinger, 2011, Vox sanguinis.

The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population.

J. Oldenburg, H. Brackmann, A. Eis-Hübinger, 1996, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

F8 genetic analysis strategies when standard approaches fail

J. Oldenburg, O. el-Maarri, A. Pavlova, 2013, Hämostaseologie.

Sequencing of the factor 8(F8) coding regions in 10 Turkish hemophilia A patients reveals three novel pathological mutations, and one rediagnosis of von Willebrand's disease type 2N

J. Oldenburg, O. el-Maarri, N. Akar, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters

E. Seifried, J. Oldenburg, N. von Ahsen, 2010, European Journal of Clinical Pharmacology.

[New insight in therapeutic anticoagulation by Coumarin derivatives].

J. Oldenburg, M. Watzka, B. Pötzsch, 2008, Hamostaseologie.

The Genetic Basis of Resistance to Anticoagulants in Rodents

J. Oldenburg, A. Fregin, S. Rost, 2005, Genetics.

The vitamin K cycle.

J. Oldenburg, M. Watzka, C. Müller-Reible, 2008, Vitamins and hormones.

Interferon-lambda serum levels in hepatitis C.

J. Nattermann, H. Nischalke, T. Sauerbruch, 2011, Journal of hepatology.

Genetics of warfarin resistance Two enzymes essential for the vitamin K cycle

J. Oldenburg, S. Rost, M. Watzka, 2017 .

Tris(3-hydroxypropyl)phosphine is superior to dithiothreitol for in vitro assessment of vitamin K 2,3-epoxide reductase activity.

Christoph A. Krettler, J. Oldenburg, M. Watzka, 2015, Analytical biochemistry.

Two enzymes catalyze vitamin K 2,3-epoxide reductase activity in mouse: VKORC1 is highly expressed in exocrine tissues while VKORC1L1 is highly expressed in brain.

J. Oldenburg, K. Czogalla, M. Watzka, 2015, Thrombosis research.

Warfarin and vitamin K compete for binding to Phe55 in human VKOR

V. Hornung, A. Biswas, J. Oldenburg, 2016, Nature Structural &Molecular Biology.

Novel mutations in the VKORC1 gene of wild rats and mice – a response to 50 years of selection pressure by warfarin?

J. Oldenburg, S. Rost, T. Jäkel, 2009, BMC Genetics.

Mitochondria: Emerging Consequential in Sickle Cell Disease

A. Biswas, J. Oldenburg, A. Madkhali, 2023, Journal of clinical medicine.

Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C.

A. Hoerauf, T. Sauerbruch, U. Spengler, 2010, Clinical science.

F8 gene: embedded in a region of genomic instability representing a hotspot of complex rearrangements

J. Oldenburg, B. Pezeshkpoor, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Lack of F8 mRNA: a novel mechanism leading to hemophilia A.

T. Haaf, H. Singer, J. Oldenburg, 2006, Blood.

Further Evidence That MicroRNAs Can Play a Role in Hemophilia A Disease Manifestation: F8 Gene Downregulation by miR-19b-3p and miR-186-5p

J. Oldenburg, Z. Sauna, C. Atreya, 2020, Frontiers in Cell and Developmental Biology.

Infiltration and clustering of MHC-II+ antigen-presenting cells in the skin of patients with atopic dermatitis.

J. Oldenburg, N. Novak, N. Garbi, 2020, The Journal of investigative dermatology.

Glycophorin A-based exclusion of red blood cells for flow cytometric analysis of platelet glycoprotein expression in citrated whole blood

J. Oldenburg, Jens Müller, B. Pötzsch, 2020, Clinical chemistry and laboratory medicine.

VKORC1: molecular target of coumarins

J. Oldenburg, S. Rost, M. Watzka, 2007, Journal of thrombosis and haemostasis : JTH.

Inter-locus as well as intra-locus heterogeneity in LINE-1 promoter methylation in common human cancers suggests selective demethylation pressure at specific CpGs

R. Fimmers, H. Fröhlich, W. Schulz, 2015, Clinical Epigenetics.

A systematic search for DNA methyltransferase polymorphisms reveals a rare DNMT3L variant associated with subtelomeric hypomethylation.

T. Wienker, T. Becker, F. Chédin, 2009, Human molecular genetics.

Beta-propiolactone UV inactivated clotting factor concentrate is the source of HIV-infection of 8 hemophilia B patients: confirmed.

R. Kaiser, J. Oldenburg, H. Brackmann, 1995, Thrombosis and haemostasis.

Familial molar tissues due to mutations in the inflammatory gene, NALP7, have normal postzygotic DNA methylation

R. Kuick, S. Hanash, Ugljesa Djuric, 2006, Human Genetics.

Bleeding diathesis in patients with mast cell activation disease

J. Oldenburg, G. Molderings, H. Hertfelder, 2011, Thrombosis and Haemostasis.

DNA methylation signature in peripheral blood reveals distinct characteristics of human X chromosome numerical aberrations

M. Nöthen, H. Fröhlich, P. Hoffmann, 2015, Clinical Epigenetics.

Molecular Genetic Analysis of a Patient with Moderate Hemophilia A and Psychomotor Developmental Delay

J. Oldenburg, I. Hainmann, S. Rost, 2013, Klinische Pädiatrie.

Deletion of human GP 1 BB and SEPT 5 is associated with Bernard-Soulier syndrome , platelet secretion defect , polymicrogyria , and develop-mental delay

P. Nurden, J. Oldenburg, I. Hainmann, 2018 .

Detection of heterozygous large deletions in the antithrombin gene using multiplex polymerase chain reaction and denatured high performance liquid chromatography.

E. Seifried, J. Oldenburg, O. el-Maarri, 2006, Haematologica.

Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema

J. Oldenburg, K. Bork, W. Kreuz, 2008, Cytogenetic and Genome Research.

Methylation of L1Hs promoters is lower on the inactive X, has a tendency of being higher on autosomes in smaller genomes and shows inter-individual variability at some loci

R. Fimmers, T. Wienker, T. Becker, 2011, Human molecular genetics.

Characterization of duplication breakpoints in the factor VIII gene

J. Oldenburg, S. Rost, M. Zimmermann, 2010, Journal of thrombosis and haemostasis : JTH.

Evidence for Mast Cell Activation in Patients with Therapy-Resistant Irritable Bowel Syndrome

J. Oldenburg, T. Frieling, G. Molderings, 2011, Zeitschrift fur Gastroenterologie.

Blood Coagulation , Fibrinolysis and Cellular Haemostasis Molecular basis of antithrombin deficiency

E. Seifried, J. Oldenburg, D. Delev, 2012 .

SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm

A. Biswas, J. Oldenburg, Mohammad S Akhter, 2021, Journal of clinical medicine.

Mutation Analysis in Hereditary Angioedema Identifies Patients at Risk for Developing Acute and Life Threatening Edema

J. Oldenburg, K. Bork, W. Kreuz, 2006 .

Mutation Analysis of the C1 Inhibitor Gene

J. Oldenburg, K. Bork, W. Kreuz, 2005 .

Misalignment of lung vessels and alveolar capillary dysplasia

J. Oldenburg, H. D. Pal, C. Wagenvoort, 1995, Histopathology.

Detailed methylation map of LINE‐1 5′‐promoter region reveals hypomethylated CpG hotspots associated with tumor tissue specificity

W. Schulz, M. Jamil, Amit Sharma, 2019, Molecular genetics & genomic medicine.

A novel missense mutation in the FGB gene (p.Gly302Arg) leading to afibrinogenemia

A. Biswas, J. Oldenburg, V. Ivaškevičius, 2016, Hämostaseologie.

The genetic diversification of the HIV type 1 gag p17 gene in patients infected from a common source.

E. Holmes, P. Simmonds, R. Kaiser, 1995, AIDS research and human retroviruses.

Parallel evolution in the V3 region of HIV type 1 after infection of hemophiliacs from a homogeneous source.

R. Kaiser, J. Oldenburg, P. Kasper, 1994, AIDS research and human retroviruses.

Diversification of HIV-1 strains after infection from a unique source.

R. Kaiser, J. Oldenburg, P. Kasper, 1993, AIDS research and human retroviruses.

Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products.

J. Oldenburg, S. Held, A. Heine, 2016, Cytotherapy.

Gain‐of‐Function Mutation in STIM1 (P.R304W) Is Associated with Stormorken Syndrome

Peter Nürnberg, Kerstin Konrad, Klaus Zerres, 2014, Human mutation.

Human Plasmacytoid Dendritic Cells Support Th17 Cell Effector Function in Response to TLR7 Ligation

G. Hartmann, T. Bieber, J. Oldenburg, 2009, The Journal of Immunology.

Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4

J. Oldenburg, H. Brackmann, S. Baylis, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Different inactivating mutations in the LU genes of three individuals with the Lutheran‐null phenotype

J. Oldenburg, M. Uchikawa, G. Daniels, 2007, Transfusion.

Characterisation of patients with Glanzmann thrombasthenia and identification of 17 novel mutations

J. Oldenburg, K. Kurnik, S. Halimeh, 2014, Thrombosis and Haemostasis.

Relevance of a single dose of 270 μg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors

J. Oldenburg, G. Auerswald, R. Zotz, 2009, Hämostaseologie.

Modelling and expression studies of two novel mutations causing factor V deficiency

E. Seifried, Tamir Chandra, J. Oldenburg, 2008, Thrombosis and Haemostasis.

Intron retention resulting from a silent mutation in the VWF gene that structurally influences the 5' splice site.

A. Biswas, J. Oldenburg, J. Driesen, 2016, Blood.

Evidence of pathogenicity of a mutation in 3′ untranslated region causing mild haemophilia A

J. Oldenburg, O. el-Maarri, K. Czogalla, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Identification of deep intronic variants in 15 haemophilia A patients by next generation sequencing of the whole factor VIII gene

J. Oldenburg, S. Rost, C. Müller, 2015, Thrombosis and Haemostasis.

A Homozygous Deep Intronic Variant Causes Von Willebrand Factor Deficiency and Lack of Endothelial-Specific Secretory Organelles, Weibel–Palade Bodies

M. Jamil, J. Oldenburg, H. Yadegari, 2022, International journal of molecular sciences.

Comparison of F13A1 gene mutations in 73 patients treated with recombinant FXIII‐A2

A. Biswas, J. Oldenburg, V. Ivaškevičius, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Genome-wide transcriptome induced by nickel in human monocytes.

M. Nöthen, A. Hoerauf, J. Deschner, 2016, Acta biomaterialia.

Three different hepatocyte transplantation techniques for enzyme deficiency disease and acute hepatic failure.

A. T. Te Velde, R. Chamuleau, J. Oldenburg, 1992, Artificial organs.

11p15 DNA-methylation analysis in monozygotic twins with discordant intrauterine development due to severe twin-to-twin transfusion syndrome

K. Hecher, J. Oldenburg, O. el-Maarri, 2014, Clinical Epigenetics.

Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A

C. Königs, P. Dönnes, S. Lacroix-Desmazes, 2019, PloS one.

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort

C. Winkler, J. Astermark, J. Oldenburg, 2009 .

A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.

K. Shianna, D. Goldstein, J. Goedert, 2013, Human molecular genetics.

Correlation of transient elastography with APRI and FIB‐4 in a cohort of patients with congenital bleeding disorders and HCV or HIV/HCV coinfection

F. Lammert, T. Sauerbruch, U. Spengler, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Homozygosity Mapping of a Second Gene Locus for Hereditary Combined Deficiency of Vitamin K-Dependent Clotting Factors (FMFD) to Chromosome 16

J. Oldenburg, A. Fregin, S. Rost, 2004 .

SOCS1 and SOCS3 Target IRF7 Degradation To Suppress TLR7-Mediated Type I IFN Production of Human Plasmacytoid Dendritic Cells

J. Oldenburg, M. Geyer, N. Novak, 2018, The Journal of Immunology.

Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter

S. Kaveri, S. Lacroix-Desmazes, J. Dimitrov, 2012 .

Whole Blood DNA Aberrant Methylation in Pancreatic Adenocarcinoma Shows Association with the Course of the Disease: A Pilot Study

J. Oldenburg, A. Gulbinas, O. el-Maarri, 2012, PloS one.

Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1

J. Oldenburg, A. Fregin, S. Rost, 2005, Thrombosis and Haemostasis.

Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population

A. Biswas, J. Oldenburg, T. Shamsi, 2017, Thrombosis Journal.

Methylation at Global LINE-1 Repeats in Human Blood Are Affected by Gender but Not by Age or Natural Hormone Cycles

T. Wienker, N. Nüsgen, H. Singer, 2011, PloS one.

The PNPLA3 rs738409 148M/M Genotype Is a Risk Factor for Liver Cancer in Alcoholic Cirrhosis but Shows No or Weak Association in Hepatitis C Cirrhosis

F. Lammert, T. Berg, J. Nattermann, 2011, PloS one.

Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis

J. Oldenburg, R. Klamroth, S. Kluge, 2020, Hämostaseologie.

Correction: Methylation at Global LINE-1 Repeats in Human Blood Are Affected by Gender but Not by Age or Natural Hormone Cycles

N. Nüsgen, H. Singer, J. Oldenburg, 2015, PloS one.

A rapid, quantitative, non-radioactive bisulfite-SNuPE- IP RP HPLC assay for methylation analysis at specific CpG sites.

J. Walter, J. Oldenburg, O. el-Maarri, 2002, Nucleic acids research.

Recurrent Intracranial Bleed in 3 Siblings: Short of a Shot of Vitamin K!

J. Oldenburg, V. Mahajan, M. Watzka, 2020, Journal of pediatric hematology/oncology.

Genetic variants of the vitamin K dependent coagulation system and intraventricular hemorrhage in preterm infants

J. Oldenburg, M. Watzka, F. Schreiner, 2014, BMC Pediatrics.

Association of COMT genotypes with S-COMT promoter methylation in growth-discordant monozygotic twins and healthy adults

R. Fimmers, M. Mattheisen, J. Oldenburg, 2011, BMC Medical Genetics.

Measurements of DNA Methylation at Seven Loci in Various Tissues of CD1 Mice

N. Nüsgen, J. Oldenburg, O. el-Maarri, 2012, PloS one.

VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation

C. Coch, G. Hartmann, H. Kölsch, 2012, European Journal of Clinical Pharmacology.

Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles

J. Oldenburg, C. Geisen, A. Fregin, 2007, Thrombosis and Haemostasis.

Methylation analysis of the promoter region and intron 1 of the factor VIII gene in haemophilia A patients

T. Haaf, J. Oldenburg, S. Rost, 2013, Hämostaseologie.

Structural and functional influences of coagulation factor XIII subunit B heterozygous missense mutants

A. Biswas, J. Oldenburg, V. Ivaškevičius, 2015, Molecular genetics & genomic medicine.

Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function

A. Biswas, J. Oldenburg, P. Petrides, 2010, Haematologica.

Mutations in haemophilia A

J. Oldenburg, R. Schwaab, H. Brackmann, 1993, British journal of haematology.

Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.

J. Oldenburg, H. Gschaidmeier, A. Pavlova, 2005 .

In vivo thrombin generation and subsequent APC formation are increased in factor V Leiden carriers.

J. Oldenburg, Jens Müller, B. Pötzsch, 2018, Blood.

11 novel Mutations in the Factor VIII encoding Gene lead to severe or moderate Hemophilia A

N. Klopp, J. Oldenburg, R. Schwaab, 2003 .

Congenital Deficiency of Vitamin K Dependent Coagulation Factors in Two Families Presents as a Genetic Defect of the Vitamin K-Epoxide-Reductase-Complex

L. Schurgers, J. Oldenburg, A. Fregin, 2000, Thrombosis and Haemostasis.

Detection of large duplications within the factor VIII gene by MLPA 1

J. Oldenburg, A. Pavlova, S. Rost, 2008, Journal of thrombosis and haemostasis : JTH.

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

B. Goh, J. Oldenburg, R. Soong, 2006, Clinical pharmacology and therapeutics.

Simultaneous Bilateral Total Knee Arthroplasty in Hemophilic Arthopathy

J. Oldenburg, H. Brackmann, G. Goldmann, 2007 .

TAVI induces an elevation of hemostasis-related biomarkers, which is not causative for post-TAVI thrombocytopenia.

J. Oldenburg, G. Nickenig, J. Sinning, 2016, International journal of cardiology.

Stratifying Cumulus Cell Samples Based on Molecular Profiling to Help Resolve Biomarker Discrepancies and to Predict Oocyte Developmental Competence

M. Montag, N. Nüsgen, M. Jamil, 2021, International journal of molecular sciences.

Adenovirus-mediated regulatable Expression of human Factor IX in vitro and in vivo

Xiaomin Wang, H. Fechner, J. Oldenburg, 2003 .

Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy

E. Seifried, J. Oldenburg, C. Geisen, 2010, Thrombosis and Haemostasis.

VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation

T. Wienker, E. Seifried, J. Oldenburg, 2005, Thrombosis and Haemostasis.

Molecular Profiling of Liver Sinusoidal Endothelial Cells in Comparison to Hepatocytes: Reflection on Which Cell Type Should Be the Target for Gene Therapy

M. Jamil, J. Oldenburg, O. el-Maarri, 2020, Hämostaseologie.

The first case of combined coagulation factor V and coagulation factor VIII deficiency in Poland due to a novel p.Tyr135Asn missense mutation in the MCFD2 gene

E. Seifried, J. Oldenburg, M. Watzka, 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID‐19 vaccines

J. Oldenburg, B. Pezeshkpoor, M. Recher, 2022, Journal of Thrombosis and Haemostasis.

Deletion of human GP1BB and SEPT5 is associated with Bernard-Soulier syndrome, platelet secretion defect, polymicrogyria, and developmental delay

P. Nurden, J. Oldenburg, I. Hainmann, 2011, Thrombosis and Haemostasis.

Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans

J. Oldenburg, A. Nebel, B. Ivandic, 2007, Thrombosis and Haemostasis.

Response to DDAVP in mild/moderate haemophilia A patients according to the underlying Factor VIII genotype

J. Oldenburg, T. Lambert, B. Guillet, 2003 .

VKCFD2 – from clinical phenotype to molecular mechanism

J. Oldenburg, K. Czogalla, M. Watzka, 2016, Hämostaseologie.

Structural Modeling Insights into Human VKORC1 Phenotypes

J. Oldenburg, K. Czogalla, M. Watzka, 2015, Nutrients.

The Arg98Trp mutation in human VKORC1 causing VKCFD2 disrupts a di-arginine-based ER retention motif.

A. Biswas, J. Oldenburg, K. Czogalla, 2014, Blood.

Genetic Predisposition to Bleeding during Oral Anticoagulant Therapy: Evidence for Common Founder Mutations (FIXVal-10 and FIXThr-10) and an Independent CpG Hotspot Mutation (FIXThr-10)

B. Lämmle, J. Oldenburg, B. Konkle, 2001, Thrombosis and Haemostasis.

Founder Effect of the Factor-IX-Propeptide-Val-10 Variant Is Responsible for Most Marcumar-lnduced Severe Haemophilia B Cases During Oral Anticoagulant Therapy — Consequences for Monitoring

B. Lämmle, J. Oldenburg, V. Ivaškevičius, 1999 .

Missense Mutations at ALA-10 in the Factor IX Propeptide: A Novel Mechanism for Severe Bleeding During Oral Anticoagulant Therapy

J. Oldenburg, W. Kress, A. Fregin, 1998 .

[The national GTH haemophilia registry as database within the scope of the German human genome project].

J. Oldenburg, R. Schwaab, W. Schramm, 2003, Hamostaseologie.

Human Vitamin K 2,3-Epoxide Reductase Complex Subunit 1-like 1 (VKORC1L1) Mediates Vitamin K-dependent Intracellular Antioxidant Function*

J. Oldenburg, G. Kirfel, M. Watzka, 2011, The Journal of Biological Chemistry.

VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites.

V. Hornung, A. Biswas, J. Oldenburg, 2018, Blood advances.

Identification of VKORC1 interaction partners by split-ubiquitin system and coimmunoprecipitation

J. Oldenburg, S. Rost, C. Müller, 2010, Thrombosis and Haemostasis.

Polymorphisms in VKORC1 and GGCX are not major genetic determinants of vitamin K-dependent coagulation factor activity in Western Germans

J. Oldenburg, M. Watzka, B. Pötzsch, 2009, Thrombosis and Haemostasis.

Structure functional insights into calcium binding during the activation of coagulation factor XIII A

P. Volkers, A. Biswas, J. Oldenburg, 2019, Scientific Reports.

NOTCH4 gene polymorphisms as potential risk factors for brain arteriovenous malformation development and hemorrhagic presentation.

R. Fimmers, J. Schramm, A. Boström, 2017, Journal of neurosurgery.

The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?

C. Lubich, J. Oldenburg, F. Horling, 2016, Pharmaceutical Research.

SNP Map of the Protein C Gene

E. Seifried, J. Oldenburg, C. Geisen, 2005 .

Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants

J. Oldenburg, Jens Müller, B. Pötzsch, 2020, Scientific Reports.

Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD

M. Jamil, J. Oldenburg, O. el-Maarri, 2021, Blood advances.

DNA methylation at selected CpG sites in peripheral blood leukocytes is predictive of gastric cancer.

J. Oldenburg, A. Gulbinas, O. el-Maarri, 2014, Anticancer research.

Short-term venous stasis induces fibrinolytic activation but not thrombin formation.

J. Oldenburg, O. Dewald, Jens Müller, 2014, Journal of atherosclerosis and thrombosis.

Retrochorionic hematoma in congenital afibrinogenemia: Resolution with fibrinogen concentrate infusions

J. Oldenburg, T. Klingebiel, V. Ivaškevičius, 2007, American journal of hematology.

Faktor-XIII-Mangelerkrankungen

J. Oldenburg, V. Ivaškevičius, A. Thomas, 2014 .

Correction to: Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population

A. Biswas, J. Oldenburg, T. Shamsi, 2017, Thrombosis Journal.

Haemophilia Inhibitor Genetics Study – evaluation of a model for studies of complex diseases using linkage and association methods

J. Astermark, J. Oldenburg, S. Donfield, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Subclinical hyperthyroidism seems not to have a significant impact on systemic anticoagulation in patients with coumarin therapy

J. Bucerius, J. Oldenburg, H. Biersack, 2008, Thrombosis and Haemostasis.

Identification of 32 novel mutations in the factor VIII gene in Indian patients with hemophilia A.

E. Seifried, J. Oldenburg, R. Saxena, 2005, Haematologica.

Analysis of F8 mRNA in haemophilia A patients with silent mutations or presumptive splice site mutations

J. Oldenburg, S. Rost, M. Zimmermann, 2013, Hämostaseologie.

▼Zoely: a new combined oral contraceptive

L. Mullany, J. Oldenburg, W. Kuhn, 2014, Drug and Therapeutics Bulletin.

How to avoid being eaten: a lymphoma's defense

J. Oldenburg, M. Watzka, A. Kuperman, 2017 .

Platelet-Dependent Thrombin Generation Induced By ADP or Activated Factor X Does Not Contribute to Increased In Vivo Thrombin Formation in Myeloproliferative Neoplasms

J. Oldenburg, P. Brossart, D. Wolf, 2018, Blood.

Coagulation Factor XIIIa Inhibitor Tridegin: On the Role of Disulfide Bonds for Folding, Stability, and Function.

A. Biswas, J. Oldenburg, Kornelia Hardes, 2019, Journal of medicinal chemistry.

In Vitro Secretion Deficits are Common Among Human Coagulation Factor XIII Subunit B Missense Mutants: Correlations with Patient Phenotypes and Molecular Models

A. Biswas, J. Oldenburg, C. Bevans, 2013, Human mutation.

Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.

J. Oldenburg, V. Jiménez‐Yuste, B. Konkle, 2023, The New England journal of medicine.

Kinetic parameters of monoclonal antibodies ESH2, ESH4, ESH5, and ESH8 on coagulation factor VIII and their influence on factor VIII activity

J. Oldenburg, R. Schwaab, T. Albert, 2009, Journal of molecular recognition : JMR.

Mutation Profiling in Congenital FXIIIA Deficiency: Detection of 6 Novel Mutations

R. Hilgenfeld, J. Oldenburg, K. Kurnik, 2005 .

Serological and Virological Markers of Human Parvovirus B19 Infection in Sera of Hemophiliacs

R. Kaiser, J. Oldenburg, H. Brackmann, 1994, Thrombosis and Haemostasis.

Abstract

J. Oldenburg, B. Guillet, A. Rafowicz, 2003 .

Transcriptome-wide analysis of filarial extract-primed human monocytes reveal changes in LPS-induced PTX3 expression levels

M. Nöthen, A. Hoerauf, J. Oldenburg, 2019, Scientific Reports.

Activated Factor XI is Increased in Plasma in Response to Surgical Trauma but not to Recombinant Activated FVII-Induced Thrombin Formation

J. Oldenburg, Jens Müller, B. Pötzsch, 2020, Journal of atherosclerosis and thrombosis.

Comprehensive Profiling of Blood Coagulation and Fibrinolysis Marker Reveals Elevated Plasmin-Antiplasmin Complexes in Parkinson’s Disease

H. Fröhlich, F. Lang, Amit Sharma, 2021, Biology.

Comprehensive Proﬁling of Blood Coagulation and Fibrinolysis Marker Reveals Elevated Plasmin-Antiplasmin Complexes in Parkinson’s Disease

H. Fröhlich, F. Lang, J. Oldenburg, 2021 .

Clinical manifestation of hemophilia A in the absence of mutations in the F8 gene that encodes FVIII: role of microRNAs

J. Oldenburg, Z. Sauna, C. Atreya, 2019, Transfusion.

Type 2B von Willebrand Disease: Early Manifestation as Neonatal Thrombocytopenia.

J. Oldenburg, A. Pavlova, B. Zieger, 2021, Hamostaseologie.

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.

J. Oldenburg, M. Ozelo, D. Quon, 2023, The New England journal of medicine.

Characterization of the mutation spectrum in a Pakistani cohort of type 3 von Willebrand disease

A. Biswas, J. Oldenburg, A. Pavlova, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Peripheral Blood Leukocyte DNA Aberrant Methylation in Gastric Cancer Patients

J. Oldenburg, A. Gulbinas, O. el-Maarri, 2013 .

Genetic Basis for Inhibitor Development

J. Oldenburg, A. Pavlova, 2011 .

GGCX variants leading to biallelic deficiency to γ‐carboxylate GRP cause skin laxity in VKCFD1 patients

V. Hornung, A. Biswas, H. Singer, 2021, Human mutation.

Massive muscle haematoma three months after starting vitamin K antagonist therapy for deep-vein thrombosis in an antithrombin deficient patient: Another case of factor IX propeptide mutation

B. Lämmle, L. Alberio, J. Oldenburg, 2011, Thrombosis and Haemostasis.

Effects of the CCR5-Δ32 Mutation on Hepatitis C Virus-Specific Immune Responses in Patients with Haemophilia

G. Feldmann, G. Ahlenstiel, J. Nattermann, 2009, Immunological Investigations.

An Alu repeat-mediated genomic GCNT2 deletion underlies congenital cataracts and adult i blood group

J. Oldenburg, G. Nürnberg, P. Nürnberg, 2011, Human Genetics.

Characterisation of two novel large F8 deletions in patients with severe haemophilia A and factor VIII inhibitors

R. Marschalek, J. Oldenburg, R. Schneppenheim, 2010, Thrombosis and Haemostasis.

Small Deletion/Insertion Mutations within Poly-A Runs of the Factor VIII Gene Mitigate the Severe Haemophilia A Phenotype

J. Oldenburg, R. Schwaab, H. Brackmann, 1998, Thrombosis and Haemostasis.

Localization and Characterization of Mutations Within the Factor VIII Gene in a Cohort of 212 Patients with Hemophilia A

J. Oldenburg, S. Rost, R. Schwaab, 2001 .

Mutation and Inhibitor Incidence in a Defined Cohort of Severely Affected Haemophilia A Patients Born After 1977

J. Oldenburg, F. Schakowski, S. Rost, 2000 .

Combined coagulation factor VIII and factor IX deficiency (CDF8F9) in a patient from Lithuania

A. Biswas, J. Oldenburg, V. Ivaškevičius, 2016, Hämostaseologie.

In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile

J. Oldenburg, A. Pavlova, J. Driesen, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Bleeding Tendency of Carriers of Hemophilia A - Dependent on the Age of the Carriers?

J. Oldenburg, W. Miesbach, I. Scharrer, 2005 .

Bleeding Symptoms in Carriers of Hemophilia A — Association to the Factor VIII Gene Mutation?

J. Oldenburg, W. Miesbach, I. Scharrer, 2004 .

Vitamin K intake and stability of oral anticoagulant treatment

J. Oldenburg, 2005, Thrombosis and Haemostasis.

Recurrent VTE in a heterozygote of the fibrinogen Aα IVS4+1G>T and Aα p.Arg168Ter mutation

J. Oldenburg, V. Ivaškevičius, B. Pötzsch, 2016, Thrombosis and Haemostasis.

Mutational spectrum and deep intronic variants in the factor VIII gene of haemophilia A patients

J. Oldenburg, S. Rost, C. Müller, 2016, Hämostaseologie.

Identification of a third rearrangement at Xq28 that causes severe hemophilia A as a result of homologous recombination between inverted repeats

J. Oldenburg, O. el-Maarri, S. Rost, 2012, Journal of thrombosis and haemostasis : JTH.

Blood Coagulation, Fibrinolysis and Cellular Haemostasis Deficiencies of antithrombin, protein C and protein S – Practical experience in genetic analysis of a large patient cohort

J. Oldenburg, A. Pavlova, J. Driesen, 2017 .

Molecular characterization of five Italian families with inherited severe factor XIII deficiency

J. Oldenburg, F. Rodeghiero, G. Castaman, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

as a somatic mosaicism De novo factor VIII gene intron 22 inversion in a female carrier presents

J. Oldenburg, O. el-Maarri, S. Rost, 2013 .

Unusual genomic rearrangements in introns 1 and 22 of the F8 gene

J. Oldenburg, S. Rost, M. Zimmermann, 2011, Hämostaseologie.

Novel point mutation in fibrinogen (Innsbruck; BβArg44Gly)

A. Griesmacher, A. Biswas, J. Oldenburg, 2015, Hämostaseologie.

Efficient factor VIII affinity purification using a small synthetic ligand

J. Oldenburg, H. Kessler, R. Schwaab, 2008, Journal of thrombosis and haemostasis : JTH.

Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein

J. Oldenburg, R. Schwaab, T. Albert, 2008, Annals of Hematology.

Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces.

A. Biswas, J. Oldenburg, K. Czogalla, 2013, Blood.

Bleeding and non-bleeding phenotypes in patients with GGCX gene mutations.

J. Oldenburg, T. Dörner, C. Geisen, 2014, Thrombosis research.

Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR‐L interaction, IL‐10 and TGF‐β

A. Hoerauf, J. Oldenburg, J. Satoguina, 2008, European journal of immunology.

Relative Hyperhomocysteinemia in Patients with Panic Disorder: A Case-Control Study

J. Oldenburg, K. Imbierowicz, D. Klingmüller, 2010, Neuropsychobiology.

Molecular Genetic Analysis in Patients with Inherited Thrombophilia and Antithrombin, Protein C or Protein S Deficiency

J. Oldenburg, M. Watzka, W. Kreuz, 2005 .

Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A

J. Oldenburg, M. Spannagl, Jens Müller, 2019, Thrombosis and Haemostasis.

Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens.

J. Oldenburg, 2015, Blood.

Patient Blood Management is Associated With a Substantial Reduction of Red Blood Cell Utilization and Safe for Patient's Outcome: A Prospective, Multicenter Cohort Study With a Noninferiority Design

P. Meybohm, E. Seifried, J. Renner, 2016, Annals of surgery.

PHAGOCYTES , GRANULOCYTES , AND MYELOPOIESIS Increased circulating levels of neurotrophins and elevated expression of their high-af fi nity receptors on skin and gut mast cells in mastocytosis

R. Fimmers, E. Wardelmann, Wei Zhao, 2013 .

Molecular basis of antithrombin deficiency.

E. Seifried, J. Oldenburg, D. Delev, 2011, Thrombosis and haemostasis.

Novel and Recurrent Mutations in the Gamma-Glutamyl Carboxylase (GGCX) Gene

E. Seifried, J. Oldenburg, C. Geisen, 2005 .

First Case of Compound Heterozygosity in the Gamma- Glutamyl Carboxylase Gene Causing Combined Deficiency of all Vitamin K-Dependent Blood Coagulation Factors

J. Oldenburg, A. Fregin, S. Rost, 2004 .

Factor 5 mutation profile in German patients with homozygous and heterozygous factor V deficiency

E. Seifried, J. Oldenburg, D. Delev, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Blood Coagulation, Fibrinolysis and Cellular Haemostasis Deficiencies of antithrombin, protein C and protein S – Practical experience in genetic analysis of a large patient cohort

J. Oldenburg, A. Pavlova, J. Driesen, 2017 .